GlassScriptPhysician profile
Sabine Bernbeck
NPI 1699729889
$4,210.35
in general payments reported to CMS, 2019-2025
38 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $529 · 2021: $754 · 2022: $406 · 2023: $905 · 2024: $722 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.61 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $514.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $410.50 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $381.91 | 2019-2022 | |
| Lilly USA, LLC | $378.52 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $220.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $183.78 | 2020-2024 | Gardasil 9, Vaxneuvance, M-M-R II |
| Amgen INC. | $149.06 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $124.67 | 2020-2025 | Shingrix, Arexvy |
| Eisai INC. | $115.63 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $113.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.46 | 2021-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $92.43 | 2020-2021 | |
| Boston Scientific Corporation | $84.78 | 2023 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $78.51 | 2019-2024 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabine Bernbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.